Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | AGXT | P21549 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933092 | 0.89 | EPHX2 (0.44) | BACE1DHFREPHX2PRMT6CYP2A6 | |
| SCHEMBL4938118 | 0.87 | AGXT (0.42) | BACE1AGXT | |
| SCHEMBL4939325 | 0.83 | BACE1 (0.45) | BACE1 | |
| SCHEMBL4933098 | 0.81 | CYP2A6 (0.35) | CYP2A6 | |
| SCHEMBL30612277 | 0.81 | — | — | |
| SCHEMBL4931268 | 0.80 | PRMT6 (0.44) | PRMT6 | |
| SCHEMBL4941227 | 0.78 | BACE1 (0.44) | BACE1CTSLKCNH2 | |
| SCHEMBL20553211 | 0.77 | MAOA (0.39) | — | |
| SCHEMBL4935935 | 0.75 | HSD17B10 (0.37) | — | |
| SCHEMBL4938110 | 0.75 | IDO1 (0.38) | KCNH2AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | BACE1 30/4885DHFR 905/4885SCN8A 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.